GCP
HUMA icon

GSA Capital Partners’s Humacyte HUMA Stock Holding History

GSA Capital Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$785K Buy
1,005,709
+755,853
+303% +$700K 0.05% 670
2026
Q1 		$152K Buy
+249,856
New +$260K 0.01% 1512
2025
Q3 		– Sell
-643,744
Closed -$1.34M – 1856
2025
Q2 		$1.34M Buy
643,744
+367,037
+133% +$705K 0.09% 287
2025
Q1 		$472K Buy
276,707
+129,270
+88% +$485K 0.04% 842
2024
Q4 		$745K Buy
147,437
+27,119
+23% +$134K 0.06% 607
2024
Q3 		$655K Sell
120,318
-103,861
-46% -$685K 0.05% 734
2024
Q2 		$1.08M Buy
224,179
+25,130
+13% +$131K 0.08% 459
2024
Q1 		$619K Sell
199,049
-238,032
-54% -$800K 0.05% 759
2023
Q4 		$1.24M Buy
437,081
+81,163
+23% +$208K 0.1% 294
2023
Q3 		$1.04M Buy
355,918
+207,333
+140% +$686K 0.09% 371
2023
Q2 		$425K Buy
+148,585
New +$536K 0.04% 842

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GSA Capital Partners's HUMA Position: Q2 2026 in Review

GSA Capital Partners increased its Humacyte (HUMA) stake by 303% in Q2 2026, buying an estimated $700K and bringing the position to 1,005,709 shares worth $785K. The position accounts for 0.05% of the portfolio, ranked #670.

GSA Capital Partners first reported a position in HUMA in Q2 2023 and has held it in 11 quarters since. The position peaked at $1.34M in Q2 2025. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • GSA Capital Partners held 1,005,709 shares of Humacyte worth $785K as of Q2 2026.
  • GSA Capital Partners bought 755,853 Humacyte shares in Q2 2026, an estimated $700K.
  • Humacyte made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #670 holding.
  • GSA Capital Partners first reported a position in Humacyte in Q2 2023 and has held it in 11 quarters since.
  • GSA Capital Partners's Humacyte position peaked at $1.34M in Q2 2025.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.